Comparative Pharmacology
Head-to-head clinical analysis: METRO I V IN PLASTIC CONTAINER versus METROGEL VAGINAL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METRO I V IN PLASTIC CONTAINER versus METROGEL VAGINAL.
METRO I.V. IN PLASTIC CONTAINER vs METROGEL-VAGINAL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metronidazole exerts its antibacterial and antiprotozoal effects by entering the microbial cell and undergoing reduction by intracellular electron transport proteins, forming reactive metabolites that interact with DNA, causing strand breakage and inhibition of nucleic acid synthesis.
Metronidazole, a nitroimidazole antimicrobial, undergoes reduction by bacterial nitroreductases to form cytotoxic intermediates that disrupt DNA helical structure, inhibiting nucleic acid synthesis and causing bacterial cell death.
IV: 500 mg every 6 h or 1 g every 12 h. For severe infections: 750 mg every 6 h. Max 4 g/day.
One applicatorful (5 g of 0.75% gel) intravaginally once daily, usually at bedtime, for 5 days.
None Documented
None Documented
8 hours (6-12 hours) in adults; prolonged in hepatic impairment
Terminal elimination half-life: 6-8 hours (prolonged in hepatic impairment; half-life may exceed 20 hours in severe hepatic disease)
Renal (60-80% as unchanged drug), fecal (6-15%), biliary (small amount)
Renal: 60-80% unchanged; fecal/biliary: 6-15%
Category C
Category C
Antibiotic (Nitroimidazole)
Antibiotic (Nitroimidazole)